The Efficacy of High-flow Nasal Cannula Oxygen Therapy in Sepsis Patients
NCT04560842 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 110
Last updated 2020-09-23
Summary
Sepsis is a heterogeneous syndrome that is caused by the host imbalance immune response. At 1991, the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference developed a definition of sepsis. After more than 20 years, it was gradually developed in 2016 to the third edition of the guidelines for sepsis(Sepsis-3). Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. According to the National Health Insurance claims database of Taiwan, The incidence rate was 772.1/100,000 persons in 2012. From 2002 to 2012, the incidence of sepsis increased by 18.7%. The mortality of severe sepsis was 17.9%. However, has increased to 33% when developed to septic shock. Even in foreign studies, the intensive care unit mortality rate can reach 40%. Although sepsis was defined in 1991, after these years, the treatment of sepsis is still a goal that must be worked hard.
According to Sepsis-3, must first use the qSOFA (quick Sepsis Related Organ Failure Assessment) to assess whether the patient's blood pressure, respiratory rate, and state of consciousness meet more than two criteria, which is sepsis. If the SOFA score (Sequential Organ Failure Assessment) is further evaluated, with at least two of the following symptoms, including poor oxygenation in the lungs, hypotension or use of a vasopressor, thrombocytopenia, conscious change (Glasgow Coma Scale), bilirubin increase and creatinine rise or oligouria. If the patient must use a vasopressor to maintain a mean arterial pressure (MAP) of 65 mmHg and serum lactate more than 18 mg/dL, it is Septic shock. In clinical assessment, qSOFA (rapid sepsis-associated organ failure assessment) can also be used to assess blood pressure, respiratory rate, and state of consciousness to confirmed sepsis. According to the above assessment conditions, patients with sepsis are highly prone to respiratory failure during the disease process. In recent trials, about 40% to 85% of patients with sepsis must be need endotracheal intubation, showing the high intubation rate. Patients after intubation may cause lung injury due to improper ventilator settings (Ventilator-induced lung injury, VILI). And 10% to 25% will be combined with pneumonia caused by the ventilator (ventilator-associated pneumonia, VAP). Mortality can reach 20% to 33%. So if we can reduce septic patient's intubation rate then we can reduce the complication caused by the ventilator.
A high flow nasal cannula (HFNC) is a relatively new device for respiratory support. Patients received high-flow conditioned oxygen therapy through a nasal prong. A number of physiological effects have been described with HFNC: pharyngeal dead space washout, a positive expiratory pressure to reduce work of breathing, improve breathing synchronization. These benefits can reduce the intubation rate.
The benefit of the HFNC in septic patients is not very clear. By this prospective study to investigate the septic patients who have been admitted to the intensive care unit. The study method is to ask the patient whether they agree to participate in the trial after the patient is transferred to the intensive care unit. The patient will randomly assign the subjects to the general oxygen therapy and the HFNC group after signing the subject consent form. This study aimed to determine whether high-flow oxygen therapy immediately would reduce the need for intubation compared with standard oxygen therapy in sepsis patients.
Conditions
- High Flow Nasal Cannula
- Sepsis Syndrome
Interventions
- DEVICE
-
A high flow oxygen device.
The HFNC group use high flow oxygen device for 48 hours
- DEVICE
-
Conventional oxygen therapy
Conventional oxygen device
Sponsors & Collaborators
-
Mackay Memorial Hospital
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-09-25
- Primary Completion
- 2021-09-24
- Completion
- 2021-09-24
Countries
- Taiwan
Study Locations
More Related Trials
-
Comparison of ECMO Use and Conventional Treatment in Adults With Septic Shock
NCT01685112 ·Status: UNKNOWN
-
The Effect of Lactate Clearance Oriented Haemodynamic Therapy on the Outcome of Patients With Septic Shock
NCT02566460 ·Status: COMPLETED ·Phase: NA
-
Pharmacokinetics and Pharmacodynamics of High Dose Ceftriaxone in Patients With Sepsis
NCT07245966 ·Status: COMPLETED
-
Endotoxin Adsorber Hemoperfusion and Microcirculation
NCT01756755 ·Status: COMPLETED ·Phase: NA
-
Outcomes of Severe Sepsis Patients in Surgical Intensive Care Units
NCT01919138 ·Status: COMPLETED
-
Sepsis Prediction by Monocyte Distribution Width and Procalcitonin
NCT04322942 ·Status: UNKNOWN
-
Procalcitonin in Diagnosing Bacteremia in the Emergency Department
NCT00174122 ·Status: UNKNOWN
-
Application of Biomarkers Change to Predict Outcome of Patient With Severe Sepsis
NCT02871895 ·Status: UNKNOWN
-
Continuos Terlipressin Infusion in Septic Shock
NCT01697410 ·Status: UNKNOWN ·Phase: NA
-
Serial Body Composition Change for Risk Prediction and Nutritional Guide in Treating Patients With Sepsis
NCT04989569 ·Status: COMPLETED ·Phase: NA
-
Microcirculatory Oxygen Uptake in Sepsis
NCT02430142 ·Status: COMPLETED
-
Prolonged Intravenous Infusion of β-lactam Antibiotics in Early Septic Patients
NCT05024565 ·Status: UNKNOWN ·Phase: NA
-
Evaluation of Serum Procalcitonin in Critically Ill Patients With Suspected Sepsis
NCT03506152 ·Status: COMPLETED
-
Clinical Trial to Evaluate MDW for Early Detection of Sepsis
NCT06267742 ·Status: ACTIVE_NOT_RECRUITING
-
A Prospective Observational Study of Sepsis
NCT05309889 ·Status: UNKNOWN
-
Procalcitonin to Shorten Antibiotics Duration in ICU Patients
NCT01379547 ·Status: UNKNOWN ·Phase: PHASE3
-
The Effect of Increasing the Mean Arterial Pressure on the Microcirculation and the Prognosis of Patients With Septic Shock
NCT04136080 ·Status: UNKNOWN ·Phase: NA
-
Emergency Department Management of Sepsis Patients: A Goal-Oriented Non-Invasive Sepsis Trial
NCT01453270 ·Status: COMPLETED ·Phase: NA
-
Strategy of Early Improvement of Tissue Oxygenation Decrease the Mortality of Severe Sepsis and Septic Shock
NCT01310790 ·Status: COMPLETED ·Phase: PHASE4
-
Therapeutic Plasma Exchange in Adult Patients With Severe Sepsis
NCT04057872 ·Status: COMPLETED ·Phase: PHASE1
-
A Trial to Assess the Effect of High Nitrogen Intake in Critically Ill Patients
NCT02106624 ·Status: COMPLETED ·Phase: NA
-
Low Dose Versus High Dose Methylene Blue in Septic Patients
NCT06005558 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Pcrit and TPP for Risk Stratification in Patients with Sepsis
NCT06657196 ·Status: COMPLETED
-
Circulatory Coherence in COVID-19 and Non-COVID-19 Patients With Sepsis
NCT04644302 ·Status: COMPLETED
-
Impact of Low Dose Ketamine Infusion in Septic Patient on Non-invasive Estimators of ICP
NCT05149586 ·Status: COMPLETED